Inovio Pharmaceuticals (INO) Non-Current Assets (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Non-Current Assets of $10.3 million for Q1 2026, down 21.61% sequentially from $13.2 million in Q4 2025, and down 32.78% YoY from $15.4 million in Q1 2025.
Inovio Pharmaceuticals (INO) Non-Current Assets (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $10.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 32.78% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.3 million (down 15.11% YoY) and the FY2025 annual result came in at $13.2 million, down 14.19% from the prior year.
- Non-Current Assets fell to $10.3 million in Q1 2026 per INO's latest filing, from $13.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $45.6 million in Q1 2022 and troughed at $10.3 million in Q1 2026.
- A 5-year average of $23.3 million and a median of $17.4 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets tumbled 56.11% in 2023, then fell 4.27% in 2025.
- Over 5 years, Non-Current Assets stood at $33.3 million in 2022, then plunged by 46.42% to $17.8 million in 2023, then decreased by 13.85% to $15.4 million in 2024, then fell by 14.19% to $13.2 million in 2025, then declined by 21.61% to $10.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $10.3 million, $13.2 million, and $14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Inovio Pharmaceuticals | 95.27 Mn | 95.27 Mn | - | 9.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.48 Mn |
| Mar 31, 2026 | 10.34 Mn |
| Dec 31, 2025 | 13.19 Mn |
| Sep 30, 2025 | 14.21 Mn |
| Jun 30, 2025 | 15.54 Mn |
| Mar 31, 2025 | 15.38 Mn |
| Dec 31, 2024 | 15.37 Mn |
| Sep 30, 2024 | 15.78 Mn |
| Jun 30, 2024 | 16.24 Mn |
| Mar 31, 2024 | 17.43 Mn |
| Dec 31, 2023 | 17.84 Mn |
| Sep 30, 2023 | 18.33 Mn |
| Jun 30, 2023 | 29.75 Mn |
| Mar 31, 2023 | 32.69 Mn |
| Dec 31, 2022 | 33.29 Mn |
| Sep 30, 2022 | 41.76 Mn |
| Jun 30, 2022 | 43.21 Mn |
| Mar 31, 2022 | 45.60 Mn |
| Dec 31, 2021 | 47.50 Mn |
| Sep 30, 2021 | 48.37 Mn |